Key findings presented in the poster at ECTRIMS include:
· 41% of people living with relapsing MS reported feeling anxious about needles or intravenous therapy
· Nearly 20% of people with relapsing MS reported delaying prescribed therapy. Of those who delayed therapy, 29% did not start treatment for more than 1 year
· 68% of neurologists believed patients would initiate therapy sooner if an oral medication were available
Current treatment recommendations indicate that treatment should be started immediately following definitive diagnosis.1,2 Oral administration of MS treatments, MS Viewpoints found, is a desired improvement to MS therapy.